Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) announced that it has initiated a second development program with R-107, the company’s proprietary nitric oxide-releasing compound. The company is currently developing R-107 as a therapy for vaccine-resistant COVID-19, influenza and other viral infections. The additional program that the company is announcing will develop R-107 as a nasal spray designed to be used prophylactically to prevent viral infections. Nasal nitric oxide prevents and reduces the rate and severity of various viral infections, including viruses responsible for the flu, the common cold and coronavirus. The R-107 nasal spray that the company is developing is designed to increase the level of nitric oxide present in the nasal cavities to kill the invading viruses, thereby reducing the rate, severity and spread of viral infections. The company believes that its R-107 nasal spray could potentially be used as a preventative measure to reduce the rate and severity of the symptoms of COVID-19 or as an early intervention to prevent viral infection from spreading beyond the nasal cavities. Professor Salvatore Cuzzocrea, President of the University of Messina and former President of the European Shock Society is working with the company, and has read and approved of the scientific disclosure in this news release. Professor Cuzzocrea has significant expertise regarding the medical use of nitric oxide and nitric oxide donors, and has published more than 600 peer reviewed papers on nitric oxide. He has conducted research and experiments with nitric oxide and nitric oxide donors since 1994, and worked closely as an advisor with the Salzman Group team that designed and invented R-107.